Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
ENANTA PHARMACEUTICALS INC (ENTA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET • Reported Positive Topline Data from Phase 1study of EDP-323, an L-Protein Inhibitor in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus ; Expect to Initiate Phase 2 Human Challenge Study in Early 4Q 2023. • Cash and Marketable Securities Totaled $392.5 Million at June 30, 2023 • Royalty Revenue for the Quarter was $18.9 Million"
06/07/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "PRODUCT CANDIDATE DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MARKET"
05/08/2023 8-K Quarterly results
Docs: "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET • Reported Positive Topline Data from Phase 2 SPRINT Clinical Study of EDP-235, a 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19 • Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET®/MAVIRET® Royalties for an Upfront Payment of $200 Million • On Track to Report Phase 1 Data of EDP-323, an L-Protein Inhibitor in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus, in June • Royalty Revenue for the Quarter was $17.8 Million"
04/27/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"TABLE OF CONTENTS",
"Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET ® /MAVIRET ® to OMERS Life Sciences for $200 Million"
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/07/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
Docs: "ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan 1. Purpose The purpose of this 2019 Equity Incentive Plan of Enanta Pharmaceuticals, Inc., a Delaware corporation , is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company’s stockholders. Except where the context otherwise requires, the term “Company” shall include any of the Company’s present or future parent or subsidiary corporations as defined in Sections 424 or of the Internal Revenue Code of..."
02/07/2023 8-K Quarterly results
Docs: "Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET • Completes Enrollment in SPRINT, a Phase 2 Clinical Study of EDP-235, a 3CL Protease Inhibitor Designed as an Oral, Once-Daily Treatment for COVID-19; Topline Data Expected in May • Expects Phase 1 Data of EDP-323, an L-Protein Inhibitor in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus , in 2Q 2023 • Expands Robust Pipeline with New Research Programs Developing SARS-CoV-2 Papain-Like Protease Inhibitors and Human Metapneumovirus /RSV Dual-Inhibitors • Revenue for the Quarter was $23.6 Million"
11/21/2022 8-K Quarterly results
08/26/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Open Market Sale AgreementSM dated August 26, 2022, by and between Enanta Pharmaceuticals, Inc. and Jefferies LLC",
"Opinion of Foley Hoag LLP"
08/08/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
05/17/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/09/2022 8-K Quarterly results
03/08/2022 8-K Quarterly results
02/08/2022 8-K Quarterly results
11/22/2021 8-K Quarterly results
Docs: "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET  Presented First Preclinical Data for EDP-235, an Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19; First-in-Human Study Planned for Early 2022  Reported Positive Clinical Data from Two Phase 1b Studies of EDP-514, a Hepatitis B Virus Core Inhibitor, in Viremic and NUC-Suppressed Chronic HBV Patients; Terminated Clinical Development of EDP-721, an Oral HBV RNA Destabilizer  Announced Decision to Pursue Combination Approaches with Farnesoid X Receptor Agonists for Non-Alcoholic Steatohepatitis Through an Out-Licensing Strategy  Royalty Revenue for the Quarter was $23...."
08/23/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
07/16/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/05/2021 8-K Quarterly results
02/08/2021 8-K Quarterly results
02/05/2021 8-K Quarterly results
12/04/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/23/2020 8-K Quarterly results
Docs: "Evercore ISI 3rd Annual Virtual HealthCONx Conference, December 1 - 3, 2020 • 39 th Annual JP Morgan Virtual Healthcare Conference, January 11 - 14, 2021 • Enanta plans to issue its fiscal first quarter 2021 financial results press release, and hold a conference call regarding those results, on February 8, 2021. Conference Call and Webcast Information Enanta will host a conference call and webcast today at 4:30 p.m. ET. To participate in the live conference call, please dial 840-0595 in the U.S. or 444-4814 for international callers. A replay of the conference call will be available starting at approximately 7:30 p.m. ET on November 23, 2020, through 11:59 p.m. ET on November 25, 2020 by dialing 859-2056 from the U.S. or 537-3406 for international callers. The passcode for bo..."
08/04/2020 8-K Quarterly results
06/30/2020 8-K Quarterly results
05/06/2020 8-K Quarterly results
03/02/2020 8-K Quarterly results
02/06/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2019 Webcast and Conference Call Today at 4:30 p.m. ET"
11/21/2019 8-K Quarterly results
Docs: "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019 Webcast and Conference Call today at 4:30 p.m. ET"
08/06/2019 8-K Quarterly results
05/07/2019 8-K Quarterly results
Docs: "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2019 Webcast and Conference Call today at 4:30 p.m. ET"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy